Autor/es:
NUÑEZ, NICOLÁS GONZALO; SCHMID, JONAS; POWER, LAURA; ALBERTI, CHIARA; KRISHNARAJAH, SINDUYA; KREUTMAIR, STEFANIE; UNGER, SUSANNE; BLANCO, SEBASTIÁN; KONIGHEIM, BRENDA; MARÍN, CONSTANZA; ONOFRIO, LUISINA; KIENZLER, JENNY CHRISTINE; COSTA-PEREIRA, SARA; INGELFINGER, FLORIAN; CERBÁN, FABIO; CHIAPELLO, LAURA; MONTES, CAROLINA; MOTRÁN, CRISTINA; DUTTO, JEREMÍAS; ALMADA, LAURA; BOFFELLI, LUCÍA; SPINSANTI, LORENA; DÍAZ, ADRIÁN; RIVAROLA, MARÍA ELISA; BIOQ, JAVIER AGUILAR; BERANEK, MAURICIO; PASINOVICH, MARINA E.; CASTELLI, JUAN M.; VIZZOTTI, CARLA; SCHAEFER, MAXIMILIAN; VILLAR-VESGA, JUAN; MUNDT, SARAH; MERTEN, CARLA HELENA; SETHI, AAKRITI; WERTHEIMER, TOBIAS; LUTZ, MIRJAM; VANOAICA, DANUSIA; SOTOMAYOR, CLAUDIA; GRUPPI, ADRIANA; MÜNZ, CHRISTIAN; CARDOZO, DIEGO; BARBÁS, GABRIELA; LOPEZ, LAURA; CARREÑO, PAULA; CASTRO, GONZALO; RABOY, ELIAS; GALLEGO, SANDRA; MORÓN, GABRIEL; CERVI, LAURA; ACOSTA RODRIGUEZ, EVA V.; MALETTO, BELKYS A.; MACCIONI, MARIANA; BECHER, BURKHARD
Resumen:
he range of vaccines developed against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) provides a unique opportunity to study immunization across different platforms. In a single-center cohort, we analyzed the humoral and cellular immune compartments following five coronavirus disease 2019 (COVID-19) vaccines spanning three technologies (adenoviral, mRNA and inactivated virus) administered in 16 combinations. For adenoviral and inactivated-virus vaccines, heterologous combinations were generally more immunogenic compared to homologous regimens. The mRNA vaccine as the second dose resulted in the strongest antibody response and induced the highest frequency of spike-binding memory B cells irrespective of the priming vaccine. Priming with the inactivated-virus vaccine increased the SARS-CoV-2-specific T cell response, whereas boosting did not. Distinct immune signatures were elicited by the different vaccine combinations, demonstrating that the immune response i